Report
Adam Karlsson ...
  • Rickard Anderkrans
  • Viktor Sundberg

Herantis Pharma - A closer look at the 12-month Parkinson’s data

Top-line data for CDNF presented without surprises Primary safety endpoint met Plans for next study to determine efficacy in the pipeline
Underlying
Herantis Pharma Oyj

Herantis Pharma Oyj. Herantis Pharma Oyj is a Finland-based pharmaceutical company. It is engaged in the development of treatments for unmet clinical needs, such as dry eye syndrome, Parkinson's disease and secondary lymphedema, among others. The Company's product development portfolio includes: Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfaticin aimed at secondary lymphedema, Cis-UCA emulsion cream for atopis dermatitis, and CDNF targeting Amyotrophic Lateral Sclerosis.

Provider
ABG Sundal Collier Sponsored
ABG Sundal Collier Sponsored

ABG Sundal Collier is the independent, Nordic investment banking powerhouse, developed over 30 years, founded on a hard working partnership culture and the ability to attract top talent.

Our strategy is to be an advisor and an intermediary, and the core product offering comprise corporate advisory services, corporate financing services and investor research and brokerage services.

Our corporate advisory team offers access to a broad financial and industrial network and unparalleled transaction experience. We provide financing to corporates through our superior Nordic and international distribution platform, and we are optimally structured for naturally matching trading flows, delivering best execution for clients.

The group employ approx. 250 staff working from the Nordic offices in Norway, Sweden and Denmark and in the offices in the key international markets US, UK and Germany. 


Analysts
Adam Karlsson

Rickard Anderkrans

Viktor Sundberg

Other Reports on these Companies
Other Reports from ABG Sundal Collier Sponsored

ResearchPool Subscriptions

Get the most out of your insights

Get in touch